🇺🇸

Broad Market

· monthly

US Pre-Market SEC Filings Roundup — July 31, 2026

Overnight filings from July 30-31, 2026, reveal a market bifurcated between strong operational performance and cautious insider behavior. Apple Inc. delivered a standout quarter with net income surging 27% YoY to $29.8B, while Sony Group and AngloGold Ashanti also reported robust top-line growth, though Sony flagged a potential slowdown with nearly flat full-year guidance. Insider selling was a dominant theme, with the CEO of Tempus AI and the Co-Chairman of Charles Schwab each selling over $10M in stock, signaling potential concerns about valuation or near-term outlook. Conversely, insider buying at Navios Maritime Partners, though small in size, offers a contrarian positive signal. Capital allocation trends are mixed: Sierra Bancorp increased its dividend while repurchasing shares, but Waton Financial's net loss widened despite a 49% revenue surge, highlighting a disconnect between growth and profitability. The gold sector is a key theme, with AngloGold Ashanti's 44% revenue surge and NOVAGOLD's merger announcement reflecting strong investor appetite for precious metals amid a $4,200/oz gold price. Overall, the data suggests a market where revenue growth is common, but margin pressure, insider selling, and cautious forward guidance warrant a selective, quality-focused approach.

23 high priority 27 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — July 30, 2026

Across the 50 filings for 2026-07-30, three dominant themes emerge: (1) active M&A and strategic transactions (ICE/MarketAxess deal, Avanos take-private, Etsy divestiture, multiple acquisitions and asset purchases), (2) capital markets activity to fund growth or shore up liquidity (registered offerings, convertible notes, credit facilities, and milestone-contingent drawdowns), and (3) leadership and governance reshuffles reflecting succession planning and operational pivots. Period-over-period comparisons show a bifurcated performance set: commodity/infrastructure and select industrials reported record quarters (Enterprise Products: net income +28% YoY; MasTec: revenue +23% YoY) while several technology and services firms reported revenue/margin softness (Forrester: revenue -10.3% YoY; Group 1 Automotive: revenue -5.6% YoY, profit decline). The most critical developments with broad market implications are ICE’s announced $5.7B purchase of MarketAxess (33% premium), which could accelerate consolidation in fixed-income marketplaces and prompt regulatory scrutiny and leverage re-rating across the sector; Enterprise Products’ record operating metrics that validate midstream resilience amid global shipping disruptions; and multiple financings (NanoViricides registered offering, T1 Energy convertible notes, Annexon $200M contingent facility) that materially change capital structures and dilution/cash runway profiles. Portfolio-level patterns: PE/strategic buyers remain active (Avanos, MarketAxess/M&A), energy & industrials show relative outperformance, while corporate boards and C-suite changes are concentrated in healthcare and industrials indicating succession readiness or cost/strategy resets. Overall, actionable signals tilt toward selectively bullish positions in high-quality energy/infrastructure names and select M&A arbitrage/credit plays, while caution is warranted in companies increasing leverage, issuing equity at narrow premiums, or showing multi-quarter margin deterioration.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 30, 2026

Today's 50 filings reveal a market bifurcated between robust top-line growth and mounting margin pressures. While 8 of 10 reporting companies posted revenue gains (avg +9.8% YoY), 5 of 10 saw margin compression averaging -120 bps, driven by cost inflation and heavy investment. A surge in M&A activity (CRH's $8.5B Arcosa deal, SoftVest's $2.2B PBT combination, and MiMedx's Sanara acquisition) signals aggressive capital deployment in infrastructure and energy, while the tech sector shows a stark divergence between data center strength (WESCO +45% YoY, Trane +130% bookings) and consumer-facing weakness (Ambev CAC -5.4% volume, Magnum Americas -1.1% revenue). Insider activity is notably absent across filings, but capital allocation patterns are clear: buybacks and dividends are being prioritized by cash-rich firms (WTW +$1.5B buyback, Virtu $0.24 dividend), while pre-revenue biotechs (Braveheart, NanoViricides) rely on dilutive offerings. The most critical development is the Eli Lilly acquisition of atai Life Sciences at $6.75/share plus CVRs, providing a clear liquidity event in the psychedelic therapeutics space. Overall, the market is rewarding scale and pricing power while punishing margin erosion, with infrastructure and AI-related plays emerging as the clear winners.

11 high priority 39 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 30, 2026

Overnight filings reveal a market bifurcated between robust operational performance and cautious insider behavior. While 15+ companies reported strong YoY revenue growth (e.g., WESCO +13%, Virtu Financial +19%, Yum China +13%), a significant wave of insider selling—particularly at Natera (6 executives), CoreWeave, and Roivant Sciences—signals potential valuation concerns or profit-taking at elevated levels. The most material corporate action is the $8.5B Arcosa acquisition by CRH, reinforcing a consolidation trend in building materials. Mixed sentiment dominates, with many companies showing top-line strength but margin compression (e.g., Solstice Advanced Materials, Magnum Ice Cream) or declining cash flows (CRH, WESCO). The IPO pipeline is active with Braveheart Bio filing for a $319M offering. Key themes include data center/AI infrastructure demand (WESCO, AITX), margin discipline challenges, and a divergence between reported earnings and underlying cash generation.

28 high priority 22 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — July 29, 2026

The July 29, 2026 filings reveal a market bifurcated between strong operational execution and acute financial distress. A clear theme of 'growth at a cost' emerges, with companies like Bandwidth and Adaptive Biotechnologies posting robust revenue growth (22% YoY each) but experiencing margin compression or widening losses. Conversely, a cluster of micro-cap and distressed companies (Nuvve, CID Holdco, PetVivo) are facing existential events like Nasdaq delistings and financing collapses. The most significant capital market activity is in the biotech and healthcare sectors, with two transformative reverse-merger transactions (Synlogic/Caldera, Processa/Vidya) that involve massive dilution for existing shareholders but provide substantial cash infusions for pipeline development. M&A activity is also prominent, with Procore's $845M acquisition of DroneDeploy and MiMedx's $350M acquisition of Sanara MedTech signaling strategic consolidation. Insider activity is limited, but CFO transitions at VF Corp, Lemonade, and Clarivate suggest a period of leadership realignment. The overall sentiment is mixed, with 24 filings showing neutral sentiment, 8 positive, 6 negative, and 6 mixed, reflecting a market that is rewarding execution but punishing any missteps.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — July 29, 2026

This digest covers 50 filings from July 29, 2026, dominated by Indian M&A, insolvency, and regulatory actions, alongside several US SPAC business combinations and Nasdaq delisting notices. A key trend is the high volume of open offers and structured acquisitions in India (Niraj Cement, Duke Offshore, 5Paisa Capital), while US markets show significant SPAC activity (Westin Acquisition, PBT Land & Minerals) and two capital market withdrawals (Astral demerger, EFC scheme). Insider activity is sparse but notable in the US, including the dilution of existing Processa stockholders (to ~0.9% ownership), signaling extreme risk. Negative signals are concentrated: MT Educare, K-Lifestyle, and ICSA India are deep in insolvency with ongoing defaults; three US companies (SCWorx, Foxx Development, Celularity) received Nasdaq deficiency notices. Unusually, a major impersonation incident was reported in a CoC meeting (K-Lifestyle). On the positive side, significant capital raisings (Processa $200M, Catalyst Acquisition $200M), strategic re-routing (RPG Life Sciences restructuring with a $700M growth fund), and a transformative healthcare SPAC merger (Westin/FCHS) offer high-upside opportunities. The key recommendation is to avoid deeply distressed Indian insolvencies and watch for delisting catalysts in the US, while selectively targeting the structured exits and operational restructurings.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 29, 2026

Today's digest (July 29, 2026) reveals a market sharply bifurcated between AI/infrastructure winners and legacy industrials facing headwinds. The standout theme is surging data center demand, with Vertiv, Generac, and Teradyne all posting exceptional results and raising guidance, while SK hynix reported a record quarterly operating profit up 557% YoY. However, this strength contrasts with weakness in traditional sectors: Ford swung to a net loss, Clarivate took a massive goodwill impairment, and ArcBest reported a GAAP loss despite revenue growth. Capital allocation patterns show aggressive share repurchases at SiteOne ($114M in H1) and debt reduction at Clarivate ($211M), while insider activity is notably absent from today's filings. The most significant corporate action is Criteo's redomiciliation from France to Luxembourg, with a planned move to the U.S. in January 2027, aiming for index inclusion. The PBT Land & Minerals S-4 filing outlines a complex restructuring of the Permian Basin Royalty Trust, converting a 75% net overriding royalty into a cost-free 15% royalty, which could dramatically improve cash flow predictability. Overall, the data suggests a 'two-speed' economy where AI infrastructure investment is a powerful tailwind for select companies, while consumer-facing and industrial names face margin pressure and demand uncertainty.

10 high priority 40 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 29, 2026

Overnight filings reveal a bifurcated market with explosive growth in AI-driven industrial and semiconductor names (Vertiv, SK hynix, Teradyne) contrasting with significant distress in legacy automotive (Ford) and data/information services (Clarivate). Insider activity is a key signal, with a massive $35M purchase at Scribe Therapeutics and a $149K director buy at MapLight Therapeutics signaling strong conviction, while a CEO sale at Accelerant Holdings under a 10b5-1 plan is a less concerning signal. Capital allocation trends show aggressive share repurchases at SiteOne Landscape Supply and debt reduction at Clarivate, while Ford's cash burn is a major red flag. Guidance changes are overwhelmingly positive, with Constellium, Vertiv, and Generac all raising full-year outlooks, pointing to sustained demand in data centers and infrastructure. The most critical development is the record performance in the semiconductor and data center supply chain, which is driving a wave of positive revisions and insider confidence.

17 high priority 33 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — July 28, 2026

The July 28, 2026, filing cycle reveals a market with significant capital reallocation and strategic pivots, but also notable leadership disruptions and financial distress. The most critical development is the sudden passing of Carpenter Technology's CEO, creating immediate leadership uncertainty in a key industrial supplier. Capital markets activity is robust, with several large-scale debt and equity transactions: Galaxy Digital's $3.5B data center financing, Conagra's $500M note offering, and Atlantic Union's $250M subordinated note issuance signal a strong appetite for corporate debt, while Entera Bio's $275M private placement highlights continued biotech funding. The healthcare sector shows a stark contrast, with Centene's operational turnaround (EPS swinging from -$0.51 to +$2.51) juxtaposed against American Shared Hospital Services' acknowledged default and forbearance agreement. A clear theme of 'capital for growth' emerges, with companies like Cadiz ($273.8M in construction contracts) and Core University Living ($303.5M acquisition) deploying significant capital into long-term infrastructure and real estate projects. However, the prevalence of dilutive financing structures (Polar Power's CEF and convertible preferred, T1 Energy's IP acquisition with stock-based payments) and the high number of routine officer changes (12+ filings) suggest a market in transition, where companies are aggressively positioning for the next cycle while managing legacy risks.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — July 28, 2026

This digest covers 50 filings from July 28, 2026, dominated by a wave of M&A, insolvency, and delisting events. A key theme is the aggressive consolidation in the Indian distressed asset market, with Authum Investment & Infrastructure and Inox Green Energy Services securing NCLT approval for the Wind World India resolution, while Astron Paper & Board Mill enters CIRP with a 99% revenue collapse. In the US, the take-private of Cross Country Healthcare by Knox Lane and ANV Group's acquisition of 81.37% of Open Lending highlight a trend of public-to-private transactions. The SPAC market shows bifurcation, with a new $200M IPO from Market Technology Acquisition Corp and a $115M IPO from Southern Cross Acquisition I Corp, contrasted by the failed $303M tender offer for Lisata Therapeutics by Kuva Labs. A significant cluster of 10 ETF delistings from Themes ETF Trust and ETF Opportunities Trust signals a potential product rationalization wave. Insider trading activity is limited, but the 15.4% stake build-up in TMT India via an open offer is notable. Capital allocation is mixed, with Denali Therapeutics generating $195M from a PRV sale, while T1 Energy takes on $133M in debt for IP acquisition.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 28, 2026

Today's digest (July 28, 2026) reveals a market bifurcated between operational strength and significant one-time charges. UPS and Polaris posted strong revenue growth but saw GAAP earnings depressed by transformation and tariff-related costs, while Centene and Hilton delivered clean beats with raised guidance. The healthcare sector saw major legal overhang removal (J&J's $5.5B talc settlement) and a large PRV monetization (Denali's $195M sale), but also a clinical-stage biotech IPO (Scribe Therapeutics) and mixed Alzheimer's data (ProMIS). A notable negative signal emerged from Rexford Industrial, which posted a massive $624.8M impairment-driven loss, and from the delisting of Vestand. Insider selling was concentrated at Celsius Holdings (two directors sold ~$13.9M combined) and Sea Ltd's COO ($1.5M sale), while capital allocation remained aggressive with Armstrong World Industries authorizing an $800M buyback and Bread Financial growing credit sales 11% YoY. The overarching theme is one of 'quality over quantity'—companies with pricing power and clean balance sheets are outperforming, while those reliant on one-time benefits or facing structural headwinds are being penalized.

24 high priority 26 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 28, 2026

Overnight filings paint a bifurcated picture: robust operational performance at blue-chips like UPS, Hilton, and CenterPoint Energy is being masked by significant one-time transformation costs (UPS) or non-operating losses (CenterPoint), creating potential value dislocations. The IPO of Scribe Therapeutics ($SCTX) at $15.00 is the most prominent capital markets event, with strong insider buying at the offer price signaling management conviction. A wave of insider option awards and stock grants at Scribe, SharpLink Gaming, and 5C Lending Partners suggests a focus on long-term incentive alignment. Conversely, a major insider sale at United Therapeutics and a 10% owner sale at Actelis Networks flash caution. The pending mega-merger between Axalta and AkzoNobel is progressing, with Axalta reporting record-low leverage. Key themes include a 'show-me' growth story at UPS, a strong travel demand signal from Hilton, and a significant order win for Ceragon in India.

33 high priority 17 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — July 27, 2026

This Material Events Monitor digest covers 50 filings from July 27, 2026, revealing a market dominated by aggressive M&A and strategic capital allocation, particularly in the biotech and energy sectors. The most significant development is argenx's $2.2 billion acquisition of Forte Biosciences, signaling a major bet on the autoimmune pipeline, while Lattice Semiconductor's acquisition of AMI targets data center AI growth. A clear sector theme is the wave of auditor changes tied to the AES Corp. merger, with three subsidiaries switching from EY to KPMG, a procedural but notable event. Several companies are aggressively refinancing to lower costs and extend maturities, including Somnigroup ($2.9B) and Target Hospitality ($660M), while others like Glucotrack and Ocean Power Technologies are resorting to dilutive debt-to-equity conversions and ATM offerings, highlighting a bifurcation in financial health. Insider activity is sparse, but the CEO succession at Cracker Barrel and the new CEO appointment at Power Solutions International are key leadership events to watch. Overall, the market is showing strong conviction in high-growth areas through M&A, while some smaller caps face liquidity and governance challenges.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — July 27, 2026

This digest covers 38 filings from July 27, 2026, dominated by corporate insolvencies, M&A activity, and delisting events. A clear theme is the acceleration of de-SPAC failures, with International Media Acquisition Corp. running low on extensions and Churchill Capital Corp IX delisting, while Future Vision II Acquisition Corp. faces a massive 65% shareholder redemption despite deal approval. The M&A landscape is bifurcated: strategic acquisitions like Lattice Semiconductor's AMI deal and Novanta's Riverpoint Medical purchase are expected to be immediately accretive, while other deals like Genco Shipping's failed takeover and AiRWA's pivot into trade highlight execution risk. Insolvency proceedings are advancing for Pradhin Limited and Simbhaoli Sugars, with the latter's CIRP resuming after a stay was vacated. Regulatory actions include a small RBI penalty on a cooperative bank and Nasdaq delisting threats for AMASS Brands and Nexalin Technology. Overall, the period shows heightened event risk in SPACs and small caps, contrasted with disciplined capital deployment by larger firms.

38 high priority 38 total filings
· daily

US SEC Filings Daily Market Digest — July 27, 2026

Today's digest reveals a market bifurcated between aggressive capital deployment and mounting regulatory/operational risks. The most significant theme is a wave of transformative M&A and strategic pivots, highlighted by argenx's $2.2B acquisition of Forte Biosciences (86% premium) and NIMU's pivot to space via Gravitics. However, this activity is juxtaposed against severe regulatory actions, most notably Trip.com's $763M penalty from China's SAMR, and a string of failed or abandoned deals (Onfolio/Paramount, IMAQ's 20th extension). Financial results are mixed: Ensign Group posted strong 17.3% revenue growth and raised guidance, while Ladder Capital saw net income fall 15.8% YoY. Insider activity is sparse but notable, with United Therapeutics' CEO selling $1.45M and Greenwich LifeSciences' CEO making small insider purchases. The forward-looking landscape is rich with catalysts, including AstraZeneca's mixed Phase III readouts and Apnimed's upcoming IPO, suggesting a high-conviction but risk-aware environment.

17 high priority 33 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 27, 2026

Overnight filings reveal a market bifurcated between aggressive capital deployment (M&A, buybacks, spin-offs) and significant regulatory/pipeline setbacks. The most critical development is the $2.2B acquisition of Forte Biosciences by argenx at an 86% premium, signaling high conviction in the autoimmune space. However, this is contrasted by Trip.com's $781M anti-monopoly penalty in China and AstraZeneca's dual pipeline outcomes (positive gastric cancer data, failed HSCT-TMA trial). From a period-over-period perspective, Ensign Group and Baker Hughes show operational strength with 17.3% and 2% sequential revenue growth respectively, while Ladder Capital and Clean Energy Technologies show deteriorating profitability (net income down 15.8% YoY and gross profit swing to loss). Insider activity is mixed: a CEO purchase at Greenwich LifeSciences contrasts with a CEO sale at United Therapeutics. Capital allocation is active, with Flex Ltd. pursuing a spin-off and multiple buyback programs (BBVA, Prudential, Ryanair). The overall theme is one of strategic repositioning, with companies pivoting into new sectors (NIMU to space, Twenty One Capital to Bitcoin operating model) while others face existential regulatory or financial headwinds (Trip.com, International Media Acquisition). The breadth of filings suggests a market actively seeking growth vectors amid a complex macro environment.

17 high priority 33 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — July 24, 2026

The July 24, 2026, filings reveal a market heavily bifurcated between aggressive capital deployment and acute financial distress. The most significant themes are a wave of high-value M&A and business combinations in the healthcare and energy sectors, with Berkshire Hathaway's $6.8B acquisition of Taylor Morrison and the Neuphoria/Scancell merger highlighting a trend of consolidation. Simultaneously, a cluster of micro-cap companies (Digital Brands Group, Healthy Extracts, VSee Health) are resorting to highly dilutive and expensive debt financing, signaling severe liquidity crises. Leadership changes are pervasive, with several notable C-suite resignations (Microchip Technology, Blackstone funds) and a trend of appointing former executives to boards (Kontoor Brands). The period-over-period data is limited, but the forward-looking statements and transaction details paint a clear picture of a market where well-capitalized firms are executing strategic growth while others are fighting for survival, creating a stark divide in investment opportunities.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — July 24, 2026

The July 24, 2026 digest reveals a market bifurcated between aggressive capital deployment and acute financial distress. A wave of M&A and strategic investments—including Berkshire Hathaway's $8.5B acquisition of Taylor Morrison and a $240M PIPE for Freenome—signals strong corporate confidence in specific sectors. However, this is contrasted by a deluge of Nasdaq delisting warnings (11 filings) and a major retail bankruptcy (QVC), indicating severe stress among smaller and leveraged companies. Period-over-period data shows strong revenue growth at Apar Industries (+29.1% YoY) and Welspun Corp (+14.9% YoY), but also significant profit declines at ACC Limited (-61.6% YoY). The most critical development is the QVC Chapter 11 confirmation, which will wipe out all equity holders, serving as a stark warning for holders of distressed retail debt. The dominant theme is a 'survival of the fittest' environment where well-capitalized firms are consolidating, while those with weak balance sheets or market valuations are being purged from public markets.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 24, 2026

Today's digest reveals a market bifurcated between aggressive capital deployment through M&A and buybacks, and significant financial distress at the micro-cap level. The most critical development is Intel's staggering $11.0B quarterly net loss, driven by a $13.6B non-cash mark-to-market charge, which overshadows its strong 25% revenue growth and gross margin improvement. In the energy sector, a major consolidation is underway with MN8 Energy's acquisition of Greenbacker, creating a top-three clean power platform. The financial sector shows mixed signals, with Flagstar Bank posting improved earnings but rising credit costs, while Woori Financial pursues an aggressive expansion strategy. Insider selling at Sea Ltd. and ASE Technology, coupled with a major insider exit filing for Upexi, signals caution in tech. Conversely, the capital allocation theme is strong, with News Corp authorizing a $1B buyback, Flagstar announcing a $250M repurchase program, and multiple companies declaring dividends. The SPAC and biotech space is active, with Perceptive Capital Solutions completing its merger with Freenome and SoundHound AI clearing final regulatory hurdles for its LivePerson acquisition. A clear theme of 'haves and have-nots' emerges, with strong balance sheets funding growth and buybacks, while cash-strapped entities like Atlantis Glory and Versus Systems face existential risks.

21 high priority 29 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 24, 2026

The overnight filing period from July 23-24, 2026, reveals a market dominated by transformative M&A activity, mixed earnings results, and significant insider selling. The most critical development is the creation of a top-three U.S. clean power platform via the Greenbacker/MN8 merger ($375M base purchase price, ~6.2 GW combined capacity), alongside SoundHound AI clearing all foreign regulatory hurdles for its LivePerson acquisition. Financial sector results are bifurcated: Flagstar Bank showed a dramatic YoY earnings turnaround (net income of $26M vs. a $78M loss), while Woori Financial posted strong QoQ net income growth (+60.5%) but declining revenue (-13.9% QoQ). A notable pattern of insider selling emerged, with executives at Cadence Design Systems, Viant Technology, and Kaspi.kz all executing pre-planned sales. Intel's Q2 results present a stark contrast: revenue grew 25% YoY to $16.1B and gross margins improved to 40.4%, but a massive $13.6B mark-to-market loss on escrowed shares drove a net loss of $11.0B, widening from a $2.9B loss a year ago. The period also saw two significant SPAC combinations close (Perceptive Capital/Freenome with $332.6M pro forma cash) and a major debt offering from Galaxy Digital ($3.5B in senior secured notes).

24 high priority 26 medium 50 total filings